Blog
What the GLP-1 and sleep studies actually found, what they don't establish, and where the marketing tends to stretch past the data. General information only — not medical advice.
- GLP-1 September 2, 2026 8 min read
A Gut Hormone Subtype Predicted Who Loses Twice as Much Weight on Tirzepatide
A Mayo Clinic study found that roughly one in four adults with obesity has a distinct gut-hormone profile linked to nearly double the weight loss on tirzepatide. Here is what the physiology shows, why the test behind it is not something you can order today, and what that means if you are on a GLP-1 and not seeing that result.
- GLP-1 August 31, 2026 7 min read
A New Mouse Study Says Semaglutide Protects Knee Cartilage — Even Without Weight Loss
A March 2026 Cell Metabolism study found semaglutide slowed cartilage damage in mice even when weight loss was blocked. Here is how that fits with the human knee-osteoarthritis trial data, and what a mouse mechanism still has to prove.
- GLP-1 August 28, 2026 8 min read
Semaglutide "Beat" Tirzepatide by 57% in a New Study — the Company That Makes Semaglutide Funded and Wrote It
A large real-world study found semaglutide cut cardiovascular risk far more than tirzepatide in people with obesity and heart disease. Every author was a Novo Nordisk employee. Here is what the data shows and what industry funding means for how to read it.
- Sleep August 26, 2026 8 min read
Tirzepatide Got Approved for Sleep Apnea in Late 2024. New Data Shows Who Actually Gets It.
A claims-data analysis of nearly 20 million adults with obstructive sleep apnea and a peer-reviewed sleep-clinic study both point to the same gap: most people who could qualify for a GLP-1 for OSA are not on one, and insurance status predicts who is.
- GLP-1 August 24, 2026 7 min read
What Happens to Your Weight Loss in Year Two on a GLP-1? New Data, With a Catch
Two new studies of 63,000+ patient records find most people who stay on a GLP-1 keep their weight loss into year two. The catch is in who made it into the dataset at all.
- GLP-1 August 21, 2026 7 min read
A Randomized Trial Tested Semaglutide for Alcohol Use Disorder — Here's What It Actually Found
A Lancet-published, placebo-controlled trial found semaglutide reduced heavy drinking days more than placebo in people with alcohol use disorder and obesity. Here is what the data shows, and why it is narrower than the headlines suggest.
- Sleep August 19, 2026 7 min read
GLP-1s, SGLT2 Inhibitors, or Exercise for Sleep Apnea? A New Comparison Answers Less Than the Headline Suggests
A network meta-analysis published August 17 ranks GLP-1 medications above SGLT2 inhibitors and aerobic exercise for reducing sleep apnea severity. The authors themselves call the ranking hypothesis-generating, not a treatment recommendation — here is why.
- GLP-1 August 17, 2026 7 min read
GLP-1s Don't Just Silence Hunger Neurons — a New Study Says They Recruit Them
A Yale mouse study published in PNAS challenges the standard explanation for how GLP-1 medications produce weight loss, and offers a possible biological reason some patients plateau or regain. Here is what the experiment showed, and why it is not yet a finding about people.
- GLP-1 August 14, 2026 7 min read
A New GLP-1 Pill Posted ~11% Weight Loss in Trials — Here's What Phase 2b Actually Means
Aleniglipron, an oral small-molecule GLP-1 candidate, published phase 2b results showing up to 11.3% placebo-adjusted weight loss. Here's what the trial found, what phase 2b does not establish, and how it relates to the compounded medications NoBsRx provides access to.
- GLP-1 August 12, 2026 7 min read
A New Study Tracked Fitbit Data on GLP-1 Users — Activity Went Down, Not Up
A retrospective study of 753 GLP-1 users with wearable-device data found daily steps and moderate activity minutes fell after starting the medication, with no evidence that weight loss led people to move more. Here is what the data shows and why that matters for muscle, not just the scale.
- Sleep August 10, 2026 8 min read
Sleep Apnea Cases Are Projected to Grow 35% by 2050 — and GLP-1s Barely Move the Number
A Lancet Respiratory Medicine model projects nearly 77 million US adults will have obstructive sleep apnea by 2050. The same model found widespread GLP-1 use would cut that by less than 5% — here is why, and why most of the 83 million who already have it don't know it.
- GLP-1 August 5, 2026 8 min read
Is There a "Best" GLP-1? A New Study Says That's the Wrong Question
A July 2026 analysis pooled 19 trials into a new scoring system comparing GLP-1 drugs and doses on heart and metabolic health, not just weight loss. Here is what the numbers show, why comparing across separate trials is not the same as testing head-to-head, and what none of it tells you about a compounded version.
- GLP-1 August 3, 2026 8 min read
Can GLP-1s Curb Addiction? A Huge Veteran Study Says Maybe — Carefully
A cohort study of 600,000+ veterans found GLP-1 medications associated with lower rates of substance use disorders, from alcohol to opioids. Here is what the data shows, what the researchers themselves flagged as limits, and why a trial is now underway to actually test it.
- Sleep August 2, 2026 7 min read
GLP-1s and Sleep Apnea: What the New Research Actually Says
A large July 2026 study links GLP-1 prescriptions to lower cardiovascular event rates in people with obstructive sleep apnea. Here is what it found, what it did not find, and why none of it tells you your own numbers.
